Document is current
Any future updates will be listed below
-
Authors
Harvey, R. Donald
Carthon, Bradley C.
Lewis, Colleen
Hossain, Mohammad S.
Zhang, Chao
Chen, Zhengjia
Harris, Wayne B.
Alese, Olatunji B.
Shaib, Walid
Bilen, Mehmet A.
Lawson, David H.
Wu, Christina
Steuer, Conor E.
El-Rayes, Bassel F.
Khuri, Fadlo R.
Lonial, Sagar
Waller, Edmund K.
Ramalingam, Suresh S.
Owonikoko, Taofeek K. https://orcid.org/0000-0002-7724-7728
-
Funding
Funding for this research was provided by:
Celgene
Novartis Pharmaceuticals Corporation
- License Information
-
More Information
Article History
Received: 16 July 2019
Revised: 15 June 2020
Accepted: 1 July 2020
First Online: 24 July 2020
Ethics approval and consent to participate
: The study was approved by the Emory University IRB. All participants provided informed consent and the study was performed in accordance with the Declaration of Helsinki.
: All relevant data pertaining to this study are included in the manuscript.
: T.K.O. served on a paid advisory board for Novartis Oncology and Celgene.
: This work was supported by Celgene Inc. with funding and free supply of lenalidomide and by Novartis Oncology with free supply of everolimus. Additional support in part by NIH/NCI 5K23CA164015 grant award (PI: T.K.O.). Research reported in this publication was also supported, in part, by the Biostatistics and Bioinformatics Shared resource of Winship Cancer Institute of Emory University and National Cancer Institute at the National Institutes of Health under award number P30CA138292. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
